Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma-Reference-Cited by-同舟云学术

Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma

Published:2016-03-09 Issue:6 Volume:173 Page:896-904
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Eyre Toby A.¹,Linton Kim M.²,Rohman Phillipa³⁴,Kothari Jaimal¹,Cwynarski Kate⁴,Ardeshna Kirit⁵,Bailey Chris⁵,Osborne Wendy L.⁶,Rowntree Clare⁷,Eden Dewi⁸,Shankara Paneesha⁸,Eyre David W.⁹,Jasani Parag¹⁰,Chaidos Aristeidis³,Collins Graham P.¹,Hatton Chris S.¹

Affiliation:

1. Department of Haematology; Churchill Hospital; Oxford University Hospitals NHS Foundation Trust; Oxford UK

2. Department of Medical Oncology; the Christie NHS Foundation Trust; Manchester UK

3. Imperial College London Centre for Haematology; Hammersmith Hospital; London UK

4. Department of Haematology; Royal Free Hospital; London UK

5. Department of Haematology; University College London Hospitals NHS Foundation Trust; London UK

6. Department of Haematology; Newcastle upon Tyne NHS Foundation Trust; London UK

7. Department of Haematology; Cardiff and Vale University Health Board; Cardiff UK

8. Department of Haematology & Stem Cell Transplantation; Birmingham Heartlands Hospital; Birmingham UK

9. Nuffield Department of Medicine; University of Oxford; Oxford UK

10. Department of Haematology; Basildon and Thurrock University Hospitals NHS Foundation Trust; Basildon UK

Funder

Julian Starmer-Smith lymphoma fund

National Institute for Health Research

UCL/UCLH Biomedical Research Centre

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14021/fullpdf

Reference24 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

2. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas;Borchmann;Haematologica,2003

3. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

4. Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma;Dybkaer;Clinical Lymphoma,2004

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term efficacy in patients with relapsed/refractory diffuse large B‐cell lymphoma achieving a complete response with pixantrone;European Journal of Haematology;2023-05-10

2. Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma;European Journal of Haematology;2022-07-26

3. GOALsin relapsedDLBCL;British Journal of Haematology;2022-06-13

4. Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network);European Journal of Haematology;2022-01-30

5. Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas;Hematological Oncology;2021-03-02